Skip to main content

Advertisement

SpringerLink
Log in

Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation

  • Original Article
  • Published:
Tumor Biology

Abstract

Breast cancer is characterized by molecular heterogeneity, and four major breast cancer subtypes have been identified, each characterized by significant differences in survival, prognosis, and response to therapy. We have studied the effects of docetaxel treatment on apoptosis and survivin expression in four breast cancer cell lines: MCF7 (luminal A: estrogen receptor-positive and progesterone receptor-positive, ErbB2-negative), BT474 (luminal B: estrogen receptor/progesterone receptor/ErbB2-positive), SKBR3 (HER2-like: estrogen receptor/progesterone receptor-negative, ErbB2-positive), and MDA-MB231 (basal-like: estrogen receptor/progesterone receptor/ErbB2-negative). We demonstrated that docetaxel-induced apoptosis and survivin upregulation (MCF7 p = 0.002, BT474 p = 0.001, SKBR3 p = 0.001) in luminal A/B and HER2-like cells, while it induced mainly necrosis and a lower rate of survivin upregulation (MDA-MB231 p = 0.035) in basal-like cells. Wortmannin, a p-Akt inhibitor, was able to revert surviving upregulation and, at the same time, induced an increase of docetaxel-dependent apoptosis, suggesting that reduced levels of survivin can sensitize tumor cells to apoptosis. These data show that the analyzed breast cancer cell lines respond differently to docetaxel, depending on their receptor expression profile and molecular phenotype. Yet, these data confirm that one of the pathways involved in taxane-related chemoresistance is the upregulation of survivin. Further studies on the molecular mechanisms of chemoresistance and on the different modalities of apoptosis induced by chemotherapeutic agents are requested to better understand how cancer cells evade cell death, in order to design new kind of anticancer agents and survivin could represent a future target for this kind of research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature. 2012;490(7418):61–70.

    Article  CAS  Google Scholar 

  2. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.

    Article  CAS  PubMed  Google Scholar 

  3. Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381–7.

    Article  CAS  PubMed  Google Scholar 

  4. Dalton WS. Mechanisms of drug resistance in breast cancer. Semin Oncol. 1990;17(7):37–9.

    CAS  PubMed  Google Scholar 

  5. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis. 2007;12(9):1543–68.

    Article  CAS  PubMed  Google Scholar 

  6. Foster FM, Owens TW, Tanianis-Hughes J, Clarke RB, Brennan K, Bundred NJ, et al. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res. 2009;11(3):R41.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Byun SS, Yeo WG, Lee SE, Lee E. Expression of survivin in renal cell carcinomas: association with pathologic features and clinical out come. Urology. 2007;69(1):34–7.

    Article  PubMed  Google Scholar 

  8. Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer. 2007;96(4):639–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res. 2007;13(20):5995–6000.

    Article  CAS  PubMed  Google Scholar 

  10. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008;27(48):6252–75.

    Article  CAS  PubMed  Google Scholar 

  11. Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev. 2012;38(7):890–903.

    Article  CAS  PubMed  Google Scholar 

  12. Vichaj V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1(3):1112–6.

    Article  Google Scholar 

  13. Papapetropoulos A, Fulton D, Mahboui K, Kalb RG, O’Connor D, Li F, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem. 2000;275(13):9102–5.

    Article  CAS  PubMed  Google Scholar 

  14. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol. 2006;18(6):609–15.

    Article  CAS  PubMed  Google Scholar 

  15. Lv YG, Yu F, Yao Q, Chen JH, Wang L. The role of survivin in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis. 2010;2(2):100–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Virrey JJ, Guan S, Li W, Schontal AH, Chen TC, Hofman FM. Increased surviving expression confers chemoresistance to tumor associated endothelial cells. Am J Pathol. 2008;173(2):575–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Siddiqa A, Long LM, Li L, Marciniak RA, Kazhdan I. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic protein sSurvivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signaling pathways. BMC Cancer. 2008;8:129.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ceballos-Cancino G, Espinosa M, Maldonado V, Melendez-Zajgla J. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene. 2007;26(54):7569–75.

    Article  CAS  PubMed  Google Scholar 

  19. Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 2005;65(23):11018–25.

    Article  CAS  PubMed  Google Scholar 

  20. Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, et al. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res. 2006;66(3):1640–7.

    Article  CAS  PubMed  Google Scholar 

  21. Jiang H, Yu J, Guo H, Song H, Chen S. Upregulation of survivin by leptin/STAT3 signaling in MCF-7 cells. Biochem Biophys Res Commun. 2008;368(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  22. Ju JH, Yang W, Oh S, Nam K, Lee KM, Noh DY, et al. HER2 stabilizes surviving while concomitantly down-regulating survivin gene transcription by suppressing Notch cleavage. Biochem J. 2013;451(1):123–34.

    Article  CAS  PubMed  Google Scholar 

  23. Wall NR, O’Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of surviving phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 2003;63(1):230–5.

    CAS  PubMed  Google Scholar 

  24. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, et al. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res. 2009;15(4):1326–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Lips EH, Mulder L, De Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, et al. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat. 2012;131(3):827–36.

    Article  CAS  PubMed  Google Scholar 

  26. Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 2007;67(11):5337–44.

    Article  CAS  PubMed  Google Scholar 

  27. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011;305(18):1873–81.

    Article  CAS  PubMed  Google Scholar 

  28. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 1996;13(6):1359–65.

    CAS  PubMed  Google Scholar 

  29. Ghanbari P, Mohseni M, Tabasinezhad M, Yousefi B, Saei AA, Sharifi S, et al. Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine. Appl Biochem Biotechnol. 2014;174(2):667–81.

    Article  CAS  PubMed  Google Scholar 

  30. Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, et al. Survivin-biology and potential as a therapeutic target in oncology. Onco Targets Ther. 2013;6:1453–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Lv YG, Yu F, Yao Q, Chen JH, Wang L. The role of survivin in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis. 2010;2(2):100–10.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Medicine Department, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy

    Francesca De Iuliis, Gerardo Salerno, Anna Giuffrida, Ludovica Taglieri & Susanna Scarpa

  2. Molecular Medicine Department, Sapienza University of Rome, 00161, Rome, Italy

    Bernardina Milana, Giovanna Rubinacci, Sabrina Giantulli, Federica Terella & Ida Silvestri

Authors
  1. Francesca De Iuliis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerardo Salerno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Giuffrida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernardina Milana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ludovica Taglieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giovanna Rubinacci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sabrina Giantulli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Federica Terella
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ida Silvestri
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Susanna Scarpa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanna Scarpa.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

De Iuliis, F., Salerno, G., Giuffrida, A. et al. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation. Tumor Biol. 37, 2603–2611 (2016). https://doi.org/10.1007/s13277-015-4075-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4075-x

Keywords

Search

Navigation